Paul G. Corn, MD, PhD

Peer-Reviewed Articles

1. Hahn AW, Chahoud J, Skelton WP, Yuan Y, Zurita-Saavedra AJ, Kovitz C, Alhalabi O, Campbell MT, Jonasch E, Lin JK, Desai M, Santos MJMN, Hwang H, Corn PG, Msaouel P, Tannir NM. A multicenter randomized phase II trial of lenvatinib plus everolimus versus cabozantinib in patients with metastatic clear-cell RCC that progressed on PD-1 immune checkpoint inhibition (LenCabo). Ann Oncol 37(2):241-249, 2026. e-Pub 2026. PMID: 41115467.
2. Mak, SL, Zhu, M, Fu, J, Liang, X, Wang, X, Yuan, F, Wang, F, Hoang, A, Song, X, Shepherd, P, Liang, D, Suh, J, Contreras, J, Dang, T, Yan, C, Figueroa, B, Mazzocco, M, Luo, A, Pradhan, B, Park, J, Bashir, M, Zhang, M, Metzger, E, Schüle, R, Jain, A, Karasik, E, Frigo, DE, Foster, BA, Lee, MG, Corn, P, Logothetis, CJ, Aparicio, A, Navone, NM, Troncoso, P, Tan, Z, Zhang, J, Lin, S, Wang, G. KDM4A promotes NEPC progression through regulation of MYC expression. Cancer Letters 638, 2026. e-Pub 2026. PMID: 41319861.
3. Corn PG, Yu G, Fan Y, Zhang M, Troncoso P, Surasi DS, Liu S, Ajani JA, Logothetis CJ, Wang G, Panaretakis T, Lin SH. Spatial immune profiling of bone-metastatic castration-resistant prostate cancer reveals radium-223 immunomodulates the bone-tumor microenvironment. Prostate Cancer Prostatic Dis, 2025. e-Pub 2025. PMID: 41454189.
4. Venkatesh N, Chauhan PK, Mukhida SS, Grewal K, Aparicio A, Pilie PG, Subudhi SK, Corn PG, Sachdeva A, Desai M, Siddiqui BA, Zurita AJ, Pain D, Gregg JR, Frigo DE, Logothetis CJ, Msaouel P, Koutroumpakis E, Hahn AW. Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone Therapy. JCO Oncol Pract:OP2500506, 2025. e-Pub 2025. PMID: 41202201.
5. Sherry, AD, Siddiqui, BA, Haymaker, CL, Fellman, B, Medina-Rosales, M, Bathala, TK, Wang, S, Liu, S, Seo, A, Kobayashi, K, Lu, H, Troncoso, P, Chun, SG, Ha, CS, Mayo, LL, Mok, H, Park, RJ, Chapin, BF, Phillips, RM, Deek, MP, Kovitz, CA, Aparicio, A, Zurita-Saavedra, A, Pilie, PG, Cohen, L, Choi, S, Reuben, A, Tran, PT, Corn, P, Subudhi, SK, Tang, C. Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer. European urology 88(5):496-509, 2025. e-Pub 2025. PMID: 40750497.
6. Barrios, S, Serafini, E, La Posta, L, Meyers, DN, Dunbar, NJ, Corn, P, Elefteriou, F, Ambrose, CG, Casarin, S, Mikos, AG, Dondossola, E. Dissecting the effects of223Radium on the bone microenvironment. Acta Pharmaceutica Sinica B 15(10):5010-5021, 2025. e-Pub 2025. PMID: 41132855.
7. Hahn AW, Tidwell RS, Pilie PG, Yu Y, Liu J, Surasi DS, Titus M, Zhang J, Venkatesh N, Panaretakis T, Gregg JR, Zurita AJ, Siddiqui BA, Corn PG, Subudhi SK, Msaouel P, Koutroumpakis E, Huff CD, Aparicio A, McQuade JL, Frigo DE, Logothetis CJ. Body composition as a determinant of the therapeutic index with androgen signaling inhibition. Prostate Cancer Prostatic Dis 28(3):802-808, 2025. e-Pub 2024. PMID: 39019979.
8. Fang, A, Chapin, BF, Shi, CW, Sun, J, Qayyum, A, Kundra, V, Corn, P, Kuban, DA, Ravizzini, G, Surasi, DS, Ma, J, Bathala, TK. Whole-body magnetic resonance imaging for staging patients with high-risk prostate cancer. Prostate Cancer and Prostatic Diseases 28(3):761-766, 2025. e-Pub 2025. PMID: 39289537.
9. Fecteau RE, Koontz BF, Hoffman KE, Halabi S, Howard LE, Anand M, George DJ, Zhang T, Berry WR, Lee WR, Harrison MR, Corn PG, Armstrong AJ. Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer. Prostate Cancer Prostatic Dis 28(2):503-505, 2025. e-Pub 2024. PMID: 38388778.
10. Zhao, Y, Ramesh, N, Xu, P, Sei, E, Hu, M, Bai, S, Troncoso, P, Aparicio, A, Logothetis, CJ, Corn, P, Navin, N, Zurita-Saavedra, A. Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy. Cancer Research 85(9):1680-1695, 2025. e-Pub 2025. PMID: 39992716.
11. Schmidt, MJ, Naghdloo, A, Prabakar, RK, Kamal, M, Cadaneanu, R, Garraway, IP, Lewis, MS, Aparicio, A, Zurita-Saavedra, A, Corn, P, Kuhn, P, Pienta, KJ, Amend, SR, Hicks, J. Polyploid cancer cells reveal signatures of chemotherapy resistance. Oncogene 44(7):439-449, 2025. e-Pub 2025. PMID: 39578659.
12. Hassanzadeh, CJ, Mohamad, O, Bruno, TL, Wang, L, Kudchakar, R, Bathala, TK, Sanders, JW, Mok, H, McGuire, SE, Kuban, DA, Hoffman, K, Nguyen, Q, Park, RJ, Thames, HD, Corn, P, Chapin, BF, Choi, S, Tang, C, Frank, SJ. Early outcomes following local salvage treatment with MRI-assisted low-dose rate brachytherapy (MARS) for MRI-visible postsurgical bed recurrences and focal intraprostatic recurrences. Brachytherapy 24(2):231-237, 2025. e-Pub 2025. PMID: 39755443.
13. Venkatesh, N, Tidwell, RS, Yu, Y, Aparicio, A, Zurita, AJ, Subudhi, SK, Siddiqui, BA, Mukhida, SS, Gregg, JR, Corn, P, Koutroumpakis, E, McQuade, JL, Frigo, DE, Pilie, PG, Huff, C, Logothetis, CJ, Hahn, AW. Body composition in recurrent prostate cancer and the role of steroidogenic genotype. Endocrine-related cancer 31(12), 2024. e-Pub 2024. PMID: 39324992.
14. Sosa, A, Rooney, MK, Thames, HD, Sanders, JW, Swanson, DM, Choi, S, Nguyen, Q, Mok, H, Kuban, DA, Ron Zhu, X, Shah, SJ, Mayo, LL, Hoffman, K, Tang, C, McGuire, SE, Sahoo, N, Zhang, X, Lee, AK, Pugh, T, Mahmood, U, Davis, JW, Chapin, BF, Corn, P, Kudchadker, R, Ausat, N, Frank, SJ. Proton therapy toxicity outcomes for localized prostate cancer. Clinical and Translational Radiation Oncology 48, 2024. e-Pub 2024. PMID: 39188999.
15. Yu, G, Corn, P, Mak, CL, Liang, X, Zhang, M, Troncoso, P, Song, JH, Lin, SC, Song, X, Liu, J, Zhang, J, Logothetis, CJ, Melancon, MP, Panaretakis, T, Wang, G, Lin, SH. Prostate cancer–induced endothelial-cell-to-osteoblast transition drives immunosuppression in the bone–tumor microenvironment through Wnt pathway–induced M2 macrophage polarization. Proceedings of the National Academy of Sciences of the United States of America 121(33), 2024. e-Pub 2024. PMID: 39102549.
16. Lin, SC, Yu, G, Corn, P, Damasco, J, Lee, Y, Song, J, Navone, NM, Logothetis, CJ, Melancon, MP, Panaretakis, T, Lin, S. Radium-223 Treatment Produces Prolonged Suppression of Resident Osteoblasts and Decreased Bone Mineral Density in Trabecular Bone in Osteoblast Reporter Mice. Cancers 16(14), 2024. e-Pub 2024. PMID: 39061241.
17. Aparicio AM, Tidwell RSS, Yadav SS, Chen JS, Zhang M, Liu J, Guo S, Pilie PG, Yu Y, Song X, Vundavilli H, Jindal S, Zhu K, Viscuse PV, Lebenthal JM, Hahn AW, Soundararajan R, Corn PG, Zurita AJ, Subudhi SK, Zhang J, Wang W, Huff C, Troncoso P, Allison JP, Sharma P, Logothetis CJ. A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 30(13):2751-2763, 2024. e-Pub 2024. PMID: 38683200.
18. Yu G, Corn PG, Mak C, Liang X, Zhang M, Troncoso P, Song J, Lin SC, Song X, Liu J, Zhang J, Logothetis C, Melancon M, Panaretakis T, Wang G, Lin S. Prostate cancer-induced endothelial-cell-to-osteoblast transition drives immnusuppression in the bone-tumor microenvironment through Wnt-pathway-induced M2 macrophage polarization. PNAS, 2024. e-Pub 2024.
19. Matin, S, Adibi, M, Shah, AY, Alhalabi, O, Corn, P, Guo, C, Amirtharaj, R, Xiao, L, Lange, S, Duose, D, Wang, S, Pal, S, Campbell, M. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. Journal of Urology 211(6):784-792, 2024. e-Pub 2024. PMID: 38573872.
20. Anselmino N, Labanca E, Shepherd PDA, Dong J, Yang J, Song X, Nandakumar S, Kundra R, Lee C, Schultz N, Zhang J, Araujo JC, Aparicio AM, Subudhi SK, Corn PG, Pisters LL, Ward JF, Davis JW, Vazquez ES, Gueron G, Logothetis CJ, Futreal A, Troncoso P, Chen Y, Navone NM. Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series. Clin Cancer Res 30(10):2272-2285, 2024. e-Pub 2024. PMID: 38488813.
21. Moussa, MJ, Chen, AH, Grana, AK, Gao, J, Shah, AY, Corn, P, Tannir, NM, Goswami, S, Wang, J, Araujo, JC, Kamat, A, Navai, N, Pettaway, CA, Adibi, M, Czerniak, BA, Guo, CC, Siefker-Radtke, AO, Campbell, M, Alhalabi, O. Clinical outcomes of frontline GemFLP in advanced urachal and non-urachal adenocarcinomas of the urinary tract. Journal of Clinical Oncology 42(4), 2024. e-Pub 2024.
22. Gentile E, Hahn AW, Song JH, Hoang A, Shepherd PDA, Ramachandran S, Navone NM, Efstathiou E, Titus M, Corn PG, Lin SH, Logothetis CJ, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
23. Yu G, Corn PG, Mak CSL, Liang X, Zhang M, Troncoso P, Song JH, Lin SC, Song X, Liu J, Zhang J, Logothetis CJ, Melancon MP, Panaretakis T, Wang G, Lin SH. Prostate cancer-induced endothelial-to-osteoblast transition generates an immunosuppressive bone tumor microenvironment. bioRxiv, 2023. e-Pub 2023. PMID: 38076845.
24. Gentile, E, Hahn, AW, Song, J, Hoang, A, Shepherd, P, Ramachandran, S, Navone, NM, Efstathiou, E, Titus, M, Corn, P, Lin, S, Logothetis, CJ, Panaretakis, T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of Resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Research Communications 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
25. Viscuse, PV, Slack Tidwell, RS, Zhang, M, Rohra, P, Zhu, K, San Lucas, FA, Konnick, E, Pilie, PG, Siddiqui, BA, Logothetis, CJ, Corn, P, Subudhi, SK, Pritchard, CC, Soundararajan, R, Aparicio, A. Evaluation of the Aggressive-Variant Prostate Cancer Molecular Signature in Clinical Laboratory Improvement Amendments (CLIA) Environments. Cancers 15(24), 2023. e-Pub 2023. PMID: 38136389.
26. Gentile E, Hahn AW, Song J, Hoang A, Shepherd P, Ramachandran S, Navone N, Efstathiou E, Titus M, Corn, PG, Lin S, Logothetis C, Panaretakis T. Monitoring Glucocorticoid Receptor in Plasma-derived Extracellular Vesicles as a Marker of resistance to Androgen Receptor Signaling Inhibition in Prostate Cancer. Cancer Res Commun 3(12):2531-2543, 2023. e-Pub 2023. PMID: 37930121.
27. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
28. Sherry AD, Corn PG, Tang C. Metastases-Targeting Radiotherapy and ADT-Reply. JAMA Oncol 9(11):1587-1588, 2023. e-Pub 2023. PMID: 37707804.
29. Geng C, Zhang MC, Manyam GC, Vykoukal JV, Fahrmann JF, Peng S, Wu C, Park S, Kondraganti S, Wang D, Robinson BD, Loda M, Barbieri CE, Yap TA, Corn PG, Hanash S, Broom BM, Pilié PG, Thompson TC. SPOP mutations target STING1 signaling in prostate cancer and create therapeutic vulnerabilities to PARP inhibitor-induced growth suppression. Clin Cancer Res 29(21):4464-4478, 2023. e-Pub 2023. PMID: 37581614.
30. Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol 9(6):825-834, 2023. e-Pub 2023. PMID: 37022702.
31. Siddiqui BA, Chapin BF, Jindal S, Duan F, Basu S, Yadav SS, Gu AD, Espejo AB, Kinder M, Pettaway CA, Ward JF, Tidwell RSS, Troncoso P, Corn PG, Logothetis CJ, Knoblauch R, Hutnick N, Gottardis M, Drake CG, Sharma P, Subudhi SK. Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer 11(3), 2023. e-Pub 2023. PMID: 36948506.
32. Sherry AD, Bathala TK, Liu S, Fellman BM, Chun SG, Jasani N, Guadagnolo BA, Jhingran A, Reddy JP, Corn PG, Shah AY, Kaiser KW, Ghia AJ, Gomez DR, Tang C. Definitive Local Consolidative Therapy for Oligometastatic Solid Tumors: Results From the Lead-in Phase of the Randomized Basket Trial EXTEND. Int J Radiat Oncol Biol Phys 114(5):910-918, 2022. e-Pub 2022. PMID: 35691448.
33. Yu G, Corn PG, Shen P, Song JH, Lee YC, Lin SC, Pan J, Agarwal SK, Panaretakis T, Pacifici M, Logothetis CJ, Yu-Lee LY, Lin SH. Retinoic Acid Receptor Activation Reduces Metastatic Prostate Cancer Bone Lesions by Blocking the Endothelial-to-Osteoblast Transition. Cancer Res 82(17):3158-3171, 2022. e-Pub 2022. PMID: 35802768.
34. Msaouel P, Goswami S, Thall PF, Wang X, Yuan Y, Jonasch E, Gao J, Campbell MT, Shah AY, Corn PG, Tam AL, Ahrar K, Rao P, Sircar K, Cohen L, Basu S, Duan F, Jindal S, Zhang Y, Chen H, Yadav SS, Shazer R, Der-Torossian H, Allison JP, Sharma P, Tannir NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Sci Transl Med 14(641):eabm6420, 2022. e-Pub 2022. PMID: 35442707.
35. Labanca E, Yang J, Shepherd PDA, Wan X, Starbuck MW, Guerra LD, Anselmino N, Bizzotto JA, Dong J, Chinnaiyan AM, Ravoori MK, Kundra V, Broom BM, Corn PG, Troncoso P, Gueron G, Logothethis CJ, Navone NM. Fibroblast Growth Factor Receptor 1 Drives the Metastatic Progression of Prostate Cancer. Eur Urol Oncol 5(2):164-175, 2022. e-Pub 2022. PMID: 34774481.
36. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Adibi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2022. e-Pub 2022. PMID: 35475152.
37. Nowakowska MK, Lei X, Wehner MR, Corn PG, Giordano SH, Nead KT. Association of Second-generation Antiandrogens With Depression Among Patients With Prostate Cancer. JAMA Netw Open 4(12):e2140803, 2021. e-Pub 2021. PMID: 34940861.
38. Chai, S, Matsumoto, N, Storgard, R, Peng, CC, Aparicio, A, Ormseth, B, Rappard, K, Cunningham, K, Kolatkar, A, Nevarez, R, Tu, KH, Hsu, CJ, Malihi, PD, Corn, P, Zurita-Saavedra, A, Hicks, J, Kuhn, P, Ruiz, C. Platelet-coated circulating tumor cells are a predictive biomarker in patients with metastatic castrate-resistant prostate cancer. Molecular Cancer Research 19(12):2036-2045, 2021. e-Pub 2021. PMID: 34462330.
39. Spetsieris, N, Boukovala, M, Alafis, I, Davis, JW, Zurita-Saavedra, A, Wang, X, Tu, S, Chapin, BF, Aparicio, A, Corn, P, Wang, J, Subudhi, SK, Araujo, JC, Papadopoulos, JN, Pruitt, L, Weldon, J, Logothetis, CJ, Efstathiou, E. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer. European Journal of Cancer 157:259-267, 2021. e-Pub 2021. PMID: 34536949.
40. Subudhi SK, Siddiqui BA, Aparicio AM, Yadav SS, Basu S, Chen H, Jindal S, Tidwell RSS, Varma A, Logothetis CJ, Allison JP, Corn PG, Sharma P. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment. J Immunother Cancer 9(10), 2021. e-Pub 2021. PMID: 34663638.
41. Tang Z, Pilié PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clin Cancer Res 27(17):4898-4909, 2021. e-Pub 2021. PMID: 34168048.
42. Wu C, Peng S, Pilié PG, Geng C, Park S, Manyam GC, Lu Y, Yang G, Tang Z, Kondraganti S, Wang D, Hudgens CW, Ledesma DA, Marques-Piubelli ML, Torres-Cabala CA, Curry JL, Troncoso P, Corn PG, Broom BM, Thompson TC. PARP and CDK4/6 Inhibitor Combination Therapy Induces Apoptosis and Suppresses Neuroendocrine Differentiation in Prostate Cancer. Mol Cancer Ther 20(9):1680-1691, 2021. e-Pub 2021. PMID: 34158347.
43. Siddiqui BA, Gheeya JS, Goswamy R, Bathala TK, Surasi DS, Gao J, Shah A, Campbell MT, Msaouel P, Goswami S, Wang J, Zurita AJ, Jonasch E, Corn PG, Aparicio AM, Siefker-Radtke AO, Sharma P, Subudhi SK, Tannir N. Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events. J Immunother Cancer 9(7), 2021. e-Pub 2021. PMID: 34326169.
44. Vardaki I, Corn P, Gentile E, Song JH, Madan N, Hoang A, Parikh NU, Guerra LD, Lee YC, Lin SC, Yu G, Santos E, Melancon M, Troncoso P, Navone NM, Gallick G, Efstathiou E, Subudhi SK, Lin SH, Logothetis C, Panaretakis T. Radium 223 treatment increase immune checkpoint expression in extracellular vesicles from the metastatic prostate cancer bone microenvironment. Clin Cancer Res 27(11):3253-3264, 2021. e-Pub 2021. PMID: 33753455.
45. Koontz BF, Hoffman KE, Halabi S, Healy P, Anand M, George DJ, Harrison MR, Zhang T, Berry WR, Corn PG, Lee WR, Armstrong AJ. Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 109(5):1271-1278, 2021. e-Pub 2021. PMID: 33259932.
46. Laccetti AL, Garmezy B, Xiao L, Economides M, Venkatesan A, Gao J, Jonasch E, Corn PG, Zurita-Saavedra A, Brown LC, Kao C, Kinsey EN, Gupta RT, Harrison MR, Armstrong AJ, George DJ, Tannir N, Msaouel P, Shah AY, Zhang T, Campbell MT. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes. Cancer Med 10(7):2341-2349, 2021. e-Pub 2021. PMID: 33650321.
47. Gerdtsson AS, Setayesh SM, Malihi PD, Ruiz C, Carlsson A, Nevarez R, Matsumoto N, Gerdtsson E, Zurita A, Logothetis C, Corn PG, Aparicio AM, Hicks J, Kuhn P. Large Extracellular Vesicle Characterization and Association with Circulating Tumor Cells in Metastatic Castrate Resistant Prostate Cancer. Cancers (Basel) 13(5):1-15, 2021. e-Pub 2021. PMID: 33801459.
48. Spetsieris N, Boukovala M, Weldon JA, Tsikkinis A, Hoang A, Aparicio A, Tu SM, Araujo JC, Zurita AJ, Corn PG, Pagliaro L, Kim J, Wang J, Subudhi SK, Tannir NM, Logothetis CJ, Troncoso P, Wang X, Wen S, Efstathiou E. A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer 19(1):22-31.e5, 2021. e-Pub 2021. PMID: 32675015.
49. Surasi, DS, Lu, Y, Corn, P, Pettaway, CA, Bathala, TK. Incidental Detection of Urothelial Carcinoma on 18F-Fluciclovine PET/CT. Clinical nuclear medicine 46(2):e114-e115, 2021. e-Pub 2021. PMID: 33156041.
50. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
51. Tannir NM, Msaouel P, Ross JA, Devine CE, Chandramohan A, Gonzalez GMN, Wang X, Wang J, Corn PG, Lim ZD, Pruitt L, Karam JA, Wood CG, Zurita AJ. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. Eur Urol Oncol 3(5):687-694, 2020. e-Pub 2020. PMID: 31272939.
52. Malihi PD, Graf RP, Rodriguez A, Ramesh N, Lee J, Sutton R, Jiles R, Ruiz Velasco C, Sei E, Kolatkar A, Logothetis C, Navin NE, Corn P, Aparicio AM, Dittamore R, Hicks J, Kuhn P, Zurita AJ. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer. Clin Cancer Res 26(15):4143-4153, 2020. e-Pub 2020. PMID: 32341031.
53. Ramesh N, Sei E, Tsai PC, Bai S, Zhao Y, Troncoso P, Corn PG, Logothetis C, Zurita AJ, Navin NE. Decoding the evolutionary response to prostate cancer therapy by plasma genome sequencing. Genome Biol 21(1):162, 2020. e-Pub 2020. PMID: 32631448.
54. Subudhi SK, Vence L, Zhao H, Blando J, Yadav SS, Xiong Q, Reuben A, Aparicio A, Corn PG, Chapin BF, Pisters LL, Troncoso P, Tidwell RS, Thall P, Wu CJ, Zhang J, Logothetis CL, Futreal A, Allison JP, Sharma P. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci Transl Med 12(537), 2020. e-Pub 2020. PMID: 32238575.
55. Schmidt AB, Lund M, Corn G, Halldorsson TI, Øyen N, Wohlfahrt J, Olsen SF, Melbye M. Dietary glycemic index and glycemic load during pregnancy and offspring risk of congenital heart defects: a prospective cohort study. Am J Clin Nutr 111(3):526-535, 2020. e-Pub 2020. PMID: 31942930.
56. Corn PG, Zhang M, Nogueras-Gonzalez GM, Xiao L, Zurita AJ, Subudhi SK, Tu SM, Aparicio AM, Coarfa C, Rajapakshe K, Huang S, Navone NM, Lin SH, Wang G, Ramachandran S, Titus MA, Panaretakis T, Gallick GE, Efstathiou E, Troncoso P, Logothetis C. A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naïve Metastatic Prostate Cancer. Clin Cancer Res 26(5):990-999, 2020. e-Pub 2020. PMID: 31941830.
57. Tang C, Hoffman KE, Allen PK, Gabel M, Schreiber D, Choi S, Chapin BF, Nguyen QN, Davis JW, Corn P, Logothetis C, Ward J, Frank SJ, Navai N, McGuire SE, Anscher M, Pisters L, Pettaway CA, Kumar R, Linson P, Tripuraneni P, Tomaszewski JJ, Patel AB, Augspurger M, Kuban DA. Contemporary prostate cancer treatment choices in multidisciplinary clinics referenced to national trends. Cancer 126(3):506-514, 2020. e-Pub 2020. PMID: 31742674.
58. Logothetis CJ, Aparicio A, Koinis F, Corn PG, Efstathiou E. Prostate Cancer: Quo Vadis?. Eur Urol 76(6):709-711, 2019. e-Pub 2019. PMID: 31300238.
59. Corn PG, Heath EI, Zurita A, Ramesh N, Xiao L, Sei E, Li-Ning-Tapia E, Tu SM, Subudhi SK, Wang J, Wang X, Efstathiou E, Thompson TC, Troncoso P, Navin N, Logothetis CJ, Aparicio AM. Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial. Lancet Oncol 20(10):1432-1443, 2019. e-Pub 2019. PMID: 31515154.
60. Shah AY, Kotecha RR, Lemke EA, Chandramohan A, Chaim JL, Msaouel P, Xiao L, Gao J, Campbell MT, Zurita AJ, Wang J, Corn PG, Jonasch E, Motzer RJ, Sharma P, Voss MH, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. Eur J Cancer 114:67-75, 2019. e-Pub 2019. PMID: 31075726.
61. Hussain M, Daignault-Newton S, Twardowski PW, Albany C, Stein MN, Kunju LP, Siddiqui J, Wu YM, Robinson D, Lonigro RJ, Cao X, Tomlins SA, Mehra R, Cooney KA, Montgomery B, Antonarakis ES, Shevrin DH, Corn PG, Whang YE, Smith DC, Caram MV, Knudsen KE, Stadler WM, Feng FY, Chinnaiyan AM. Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012. J Clin Oncol 36(10):991-999, 2018. e-Pub 2018. PMID: 29261439.
62. Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway inNeuroendocrine Prostate Cancer. Clin Cancer Res 24(3):696-707, 2018. e-Pub 2018. PMID: 29138344.
63. Armstrong AJ, Antonarakis ES, Taplin ME, Kelly WK, Beltran H, Fizazi K, Dahut WL, Shore N, Slovin S, George D, Carducci MA, Corn P, Danila D, Dreicer R, Heath E, Rathkopf D, Liu G, Nanus D, Stein M, Smith MR, Sternberg C, Wilding G, Nelson PS, Halabi S, Kantoff P, Clarke NW, Evans CP, Heidenreich A, Mottet N, Gleave M, Morris MJ, Scher HI. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. Ann Oncol. e-Pub 2017. PMID: 29088323.
64. Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemother Pharmacol 80(3):583-589, 2017. e-Pub 2017. PMID: 28730293.
65. Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal 10(480), 2017. e-Pub 2017. PMID: 28536297.
66. Carlsson A, Kuhn P, Luttgen MS, Dizon KK, Troncoso P, Corn PG, Kolatkar A, Hicks JB, Logothetis CJ, Zurita AJ. Paired high-content analysis of prostate cancer cells in bone marrow and blood characterizes increased androgen receptor expression in tumor cell clusters. Clin Cancer Res 23(7):1722-1732, 2017. e-Pub 2017. PMID: 27702818.
67. Jonasch E, Hasanov E, Corn PG, Moss T, Shaw KR, Stovall S, Marcott V, Gan B, Bird S, Wang X, Do KA, Altamirano PF, Zurita AJ, Doyle LA, Lara PN, Tannir NM. A Randomized Phase 2 Study of MK-2206 versus Everolimus in Refractory Renal Cell Carcinoma. Ann Oncol 28(4):804-808, 2017. e-Pub 2017. PMID: 28049139.
68. Matrana MR, Baiomy A, Campbell M, Alamri S, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Elsayes KM, Tannir NM. Outcomes of Patients With Metastatic Non-Clear-Cell Renal Cell Carcinoma Treated With Pazopanib. Clin Genitourin Cancer 15(2):e205-e208, 2017. e-Pub 2017. PMID: 27568124.
69. Karanika S, Karantanos T, Li L, Wang J, Park S, Yang G, Zuo X, Song JH, Maity SN, Manyam GC, Broom B, Aparicio AM, Gallick GE, Troncoso P, Corn PG, Navone N, Zhang W, Li S, Thompson TC. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling. Cell Rep 18(8):1970-1981, 2017. e-Pub 2017. PMID: 28228262.
70. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Lin SH, Satcher RL, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of Patients With Metastatic Renal Cell Carcinoma and Bone Metastases in the Targeted Therapy Era. Clin Genitourin Cancer. e-Pub 2017. PMID: 28216278.
71. Basourakos SP, Li L, Aparicio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Curr Med Chem. e-Pub 2016. PMID: 27978798.
72. Bilen MA, Cauley DH, Atkinson BJ, Chen HC, Kaya DH, Wang X, Vikram R, Tu SM, Corn PG, Kim J. Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clin Genitourin Cancer. e-Pub 2016. PMID: 28038931.
73. Matrana MR, Bathala T, Campbell MT, Duran C, Shetty A, Teegavarapu P, Kalra S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience. BJU Int 118(2):264-71, 2016. e-Pub 2016. PMID: 26573089.
74. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. e-Pub 2016. PMID: 27331874.
75. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. BJU Int 117(5):761-5, 2016. e-Pub 2016. PMID: 26032863.
76. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-62, 2016. e-Pub 2016. PMID: 26343003.
77. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 34(12):1402-18, 2016. e-Pub 2016. PMID: 26903579.
78. Maiti A, Brown RE, Corn PG, Murthy R, Ganeshan DM, Tsimberidou AM, Subbiah V. Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. Clin Genitourin Cancer 14(2):e187-93, 2016. e-Pub 2016. PMID: 26684814.
79. Aparicio AM, Shen L, Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn P, Thompson TC, Broom B, Baggerly K, Maity SN, Logothetis CJ. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers. Clin Cancer Res 22(6):1520-30, 2016. e-Pub 2016. PMID: 26546618.
80. Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR-2 as Targets for Growth Inhibition of Prostate Cancer. Clin Cancer Res 22(1):107-21, 2016. e-Pub 2016. PMID: 26272062.
81. Dayyani F, Zurita AJ, Nogueras-González GM, Slack R, Millikan RE, Araujo JC, Gallick GE, Logothetis CJ, Corn PG. The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer 16:721, 2016. e-Pub 2016. PMID: 27599544.
82. Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, Troncoso P, Davis J, Pettaway C, Ward J, Frazier ML, Logothetis C, Kolonin MG. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 7:11674, 2016. e-Pub 2016. PMID: 27241286.
83. Lee YC, Lin SC, Yu G, Cheng CJ, Liu B, Liu HC, Hawke DH, Parikh NU, Varkaris A, Corn P, Logothetis C, Satcher RL, Yu-Lee LY, Gallick GE, Lin SH. Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. Cancer Res 75(22):4949-59, 2015. e-Pub 2015. PMID: 26530902.
84. Campbell MT, Millikan RE, Altinmakas E, Xiao L, Wen SJ, Siefker-Radtke AO, Aparicio A, Corn PG, Tannir NM. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma. Clin Genitourin Cancer 13(3):218-24, 2015. e-Pub 2015. PMID: 25465491.
85. Basch E, Autio KA, Smith MR, Bennett AV, Weitzman AL, Scheffold C, Sweeney C, Rathkopf DE, Smith DC, George DJ, Higano CS, Harzstark AL, Sartor AO, Gordon MS, Vogelzang NJ, de Bono JS, Haas NB, Corn PG, Schimmoller F, Scher HI. Effects of Cabozantinib on Pain and Narcotic Use in Patients with Castration-resistant Prostate Cancer: Results from a Phase 2 Nonrandomized Expansion Cohort. Eur Urol 67(2):310-8, 2015. e-Pub 2015. PMID: 24631409.
86. Bilen MA, Johnson MM, Mathew P, Pagliaro LC, Araujo JC, Aparicio A, Corn PG, Tannir NM, Wong FC, Fisch MJ, Logothetis CJ, Tu SM. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer 121(1):69-76, 2015. e-Pub 2015. PMID: 25155428.
87. Smith MR, Sweeney CJ, Corn PG, Rathkopf DE, Smith DC, Hussain M, George DJ, Higano CS, Harzstark AL, Sartor AO, Vogelzang NJ, Gordon MS, de Bono JS, Haas NB, Logothetis CJ, Elfiky A, Scheffold C, Laird AD, Schimmoller F, Basch EM, Scher HI. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. Journal of Clinical Oncology 32(30):3391-9. e-Pub 2014. PMID: 25225437.
88. Wan X, Corn PG, Yang J, Palanisamy N, Starbuck MW, Efstathiou E, Tapia EM, Zurita AJ, Aparicio A, Ravoori MK, Vazquez ES, Robinson DR, Wu YM, Cao X, Iyer MK, McKeehan W, Kundra V, Wang F, Troncoso P, Chinnaiyan AM, Logothetis CJ, Navone NM. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med 6(252):252ra122, 2014. e-Pub 2014. PMID: 25186177.
89. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer. e-Pub 2014. PMID: 25087088.
90. Hussain M, Corn PG, Michaelson MD, Hammers H, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Lin HM, George DJ. Phase II Study of Single Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen. Clin Cancer Res. e-Pub 2014. PMID: 24965748.
91. Li L, Chang W, Yang G, Ren C, Park S, Karantanos T, Karanika S, Wang J, Yin J, Shah PK, Takahiro H, Dobashi M, Zhang W, Efstathiou E, Maity SN, Aparicio AM, Li Ning Tapia EM, Troncoso P, Broom B, Xiao L, Lee HS, Lee JS, Corn PG, Navone N, Thompson TC. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 7(326):ra47, 2014. e-Pub 2014. PMID: 24847116.
92. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev. e-Pub 2014. PMID: 24522479.
93. Corn PG, Wang F, McKeehan WL, Navone N. Targeting Fibroblast Growth Factor Pathways in Prostate Cancer. Clin Cancer Res 19(21):5856, 2013. e-Pub 2013. PMID: 24052019.
94. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, Andersson BS. The histone deacetylase inhibitor SAHA sensitizes AML cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. Leuk Lymphoma. e-Pub 2013. PMID: 24144307.
95. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 2013. e-Pub 2013. PMID: 23810246.
96. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules. J Urol. e-Pub 2013. PMID: 24018239.
97. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: management, predictors, and outcomes. BJU Int. e-Pub 2013. PMID: 24053120.
98. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. Clin Cancer Res. e-Pub 2013. PMID: 23649003.
99. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene. e-Pub 2013. PMID: 23752182.
100. Abouharb S, Corn PG. Optimal Therapy Sequencing in Metastatic Castration-Resistant Prostate Cancer. Curr Oncol Rep. e-Pub 2013. PMID: 23568599.
101. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D, Depetrillo TA, Mathew P. Sunitinib Plus Androgen Deprivation and Radiation Therapy for Patients With Localized High-Risk Prostate Cancer: Results From a Multi-institutional Phase 1 Study. Int J Radiat Oncol Biol Phys. e-Pub 2013. PMID: 23541810.
102. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol 31(4):412-9, 2013. e-Pub 2013. PMID: 23169517.
103. Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials. Br J Cancer 107(9):1547-53, 2012. e-Pub 2012. PMID: 23033003.
104. McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA. PSA Response to Neoadjuvant Androgen Deprivation Therapy Is a Strong Independent Predictor of Survival in High-Risk Prostate Cancer in the Dose-Escalated Radiation Therapy Era. Int J Radiat Oncol Biol Phys. e-Pub 2012. PMID: 23102837.
105. Corn PG. The tumor microenvironment in prostate cancer: elucidating molecular pathways for therapy development. Cancer Management and Research 4:183-193, 2012. e-Pub 2012.
106. Gallick GE, Corn PG, Zurita AJ, Lin SH. Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer. Future Med Chem 4(1):107-19, 2012. e-Pub 2012. PMID: 22168167.
107. Varkaris A, Corn PG, Gaur S, Dayyani F, Logothetis CJ, Gallick GE. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Investig Drugs. e-Pub 2011. PMID: 22035268.
108. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel Therapies for Metastatic Castrate-Resistant Prostate Cancer. J Natl Cancer Inst. e-Pub 2011. PMID: 21917607.
109. Corn PG. Using methylation analysis to assess tumor heterogeneity in familial breast cancer. Cancer Biol Ther 11(12). e-Pub 2011. PMID: 21577053.
110. Tsao CC, Corn PG. MDM-2 antagonists induce p53-dependent cell cycle arrest but not cell death in renal cancer cell lines. Cancer Biol Ther 10(12). e-Pub 2010. PMID: 20953142.
111. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol. e-Pub 2010. PMID: 21115604.
112. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Cin PD, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer. e-Pub 2010. PMID: 20665500.
113. Corn PG, Thompson TC. Identification of a novel prostate cancer biomarker, caveolin-1: Implications and potential clinical benefit. Dovepress: Cancer Management and Research 2010:2:11-122, 2010. e-Pub 2010.
114. Valdez BC, Li Y, Murray D, Corn P, Champlin RE, Andersson BS. 5-Aza-2'-deoxycytidine sensitizes busulfan-resistant myeloid leukemia cells by regulating expression of genes involved in cell cycle checkpoint and apoptosis. Leuk Res 34(3):364-72, 2010. e-Pub 2010. PMID: 19732952.
115. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront randomized phase II trial of sorafenib versus sorafenib and low-dose interferon alpha in patients with advanced renal cell carcinoma. Cancer 116(1):57-65, 2010. e-Pub 2010. PMID: 19862815.
116. Corn PG. Methylation marks the path for biomarker development in breast cancer research. Cancer Biol Ther 8(23):2260-62, 2009. e-Pub 2009. PMID: 19901521.
117. Araujo JC, Poblenz A, Corn P, Parikh NU, Starbuck MW, Thompson JT, Lee F, Logothetis CJ, Darnay BG. Dasatinib inhibits both osteoclast activation and prostate cancer PC-3 cell-induced osteoclast formation. Cancer Biol Ther 8(22):2151-7, 2009. e-Pub 2009. PMID: 19855158.
118. Jonasch E, Wood CG, Matin SF, Tu SM, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC, Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 2009. e-Pub 2009. PMID: 19636008.
119. Pataer A, Swisher SG, Roth JA, Logothetis CJ, Corn PG. Inhibition of RNA-dependent protein kinase (PKR) leads to cancer cell death and increases chemosensitivity. Cancer Biol Ther 8(3):245-52, 2009. e-Pub 2009. PMID: 19106640.
120. Tsao CC, Teh BT, Jonasch E, Shreiber-Agus N, Efstathiou E, Hoang A, Czerniak B, Logothetis C, Corn PG. Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis. Cancer Biol Ther 7(10):1619-27, 2008. e-Pub 2008. PMID: 19018165.
121. Kojima K, Shimanuki M, Shikami M, Samudio IJ, Ruvulo V, Corn P, Hanoaka N, Konopleva M, Andreef M, Nakakuma H. The dual P13 kinase/mTOR inhibotor P1-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22(9):1728-36, 2008. e-Pub 2008. PMID: 18548093.
122. Corn PG. Genome-wide profilling of methylated promoters in pancreatic adenocarcinoma:defining the pancreatic cancer epigenome. Cancer Biol Ther 7(7):1157-9, 2008. e-Pub 2008. PMID: 18698160.
123. Corn PG. Hypoxic regulation of miR-210: Shrinking targets expand HIF-1's influence. Cancer Biol Ther 7(2):265-7, 2008. e-Pub 2008. PMID: 18347426.
124. Corn PG, El-Deiry WS. Microarray analysis of p53-dependent gene expression in response to hypoxia and DNA damage. Cancer Biol Ther 6(12):1858-66, 2007. e-Pub 2007. PMID: 18087215.
125. Corn PG. Reactivation of p53 function with a demethylating agent. Cancer Biol Ther 5(9):1161-2, 2006. e-Pub 2006. PMID: 17012838.
126. Corn PG, Ricci MS, Scata KA, Arsham AM, Simon MC, Dicker DT, El-Deiry WS. Mx1 is induced by hypoxia in a HIF-1 dependent manner and protects cells from c-Myc-induced apoptosis. Cancer Biol Ther 4(11):1285-94, 2005. e-Pub 2005. PMID: 16319523.
127. Rikhof B, Corn PG, El-Deiry WS. Caspase 10 levels are increased following DNA damage in a p53-dependent manner. Cancer Biol Ther 2(6):707-12, 2003. e-Pub 2003. PMID: 14688482.
128. Corn PG, McDonald ER, Herman JG, El-Deiry WS. Tat-binding protein-1, a component of the 26S proteasome, contributes to the E3 ubiquitin ligase function of the von Hippel-Lindau protein. Nat Genet 3(3):229-37, 2003. e-Pub 2003. PMID: 14556007.
129. Corn PG, Summers MK, Fogt F, Virmani AK, Gazdar AF, Halazonetis TD, El-Deiry WS. Frequent hypermethylation of the 5' CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24(1):47-51, 2003. e-Pub 2003. PMID: 12538348.
130. Corn PG, Heath EI, Heitmiller R, Fogt F, Forastiere AA, Herman JG, Wu TT. Frequent hypermethylation of the 5' CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res 7(9):2765-9, 2001. e-Pub 2001. PMID: 11555590.
131. Nicholson SA, Okby NT, Khan MA, Welsh JA, McMenamin MG, Travis WD, Jett JR, Tazelaar HD, Trastek V, Pairolero PC, Corn PG, Herman JG, Liotta LA, Caporaso NE, Harris CC. Alterations of p14ARF, p53, and p73 genes involved in the E2F-1-mediated apoptotic pathways in non-small cell lung carcinoma. Cancer Res 61(4):5636-43, 2001. e-Pub 2001. PMID: 11454718.
132. Esteller M, Cordon-Cardo C, Corn PG, Meltzer SJ, Pohar KS, Watkins DN, Capella G, Peinado MA, Matias-Guiu X, Prat J, Baylin SB, Herman JG. p14ARF silencing by promoter hypermethylation mediates abnormal intracellular localization of MDM2. Cancer Res 61(7):2816-21, 2001. e-Pub 2001. PMID: 11306450.
133. Corn PG, Esteller M, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 61(8):3225-9, 2001. e-Pub 2001. PMID: 11309270.
134. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-cadherin expression is silenced by 5'CpG island methylation in acute leukemia. Clin Cancer Res 6(11):4243-8, 2000. e-Pub 2000. PMID: 11106238.
135. Esteller M, Avizienyte E, Corn PG, Lothe RA, Baylin SB, Aaltonen LA, Herman JG. Epigenetic inactivation of LKB1 in primary tumors associated with the Peutz-Jeghers syndrome. Oncogene 19(1):164-8, 2000. e-Pub 2000. PMID: 10644993.
136. Corn PG, Kuerbitz SJ, van Noesel MM, Esteller M, Compitello N, Baylin SB, Herman JG. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5'CpG island methylation. Cancer Res 59(14):3352-6, 1999. e-Pub 1999. PMID: 10416592.
137. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59(4):798-802, 1999. e-Pub 1999. PMID: 10029065.
138. Esteller M, Corn PG, Urena JM, Gabrielson E, Baylin SB, Herman JG. Inactivation of glutathione S-transferase P1 gene by promoter hypermethylation in human neoplasia. Cancer Res 58(20):4515-8, 1998. e-Pub 1998. PMID: 9788592.
139. Corn PG, Anders J, Takala AK, Käyhty H, Hoiseth SK. Genes involved in haemophilus influenzae type b capsule expression are frequently amplified. J Infect Dis 167(2):356-64, 1993. e-Pub 1993. PMID: 8421169.
140. Hoiseth SK, Corn PG, Anders J. Amplification status of capsule genes in Haemophilus influenzae type b clinical isolates. J Infect Dis 165 Suppl 1:S114, 1992. e-Pub 1992. PMID: 1588141.
141. Corn PG, Mulroney SE, Haramati A. Restoration of a phosphaturic response to parathyroid hormone in the immature rat. Pediatr Res 26(1):54-7, 1989. e-Pub 1989. PMID: 2771508.

Review Articles

1. Venkatesh, N, Tidwell, R, Yu, Y, Aparicio, A, Zurita-Saavedra, A, Subudhi, SK, Siddiqui, BA, Gregg, JR, Corn, P, Msaouel, P, Koutroumpakis, E, McQuade, JL, Frigo, DE, Pilie, PG, Logothetis, CJ, Huff, C, Hahn, AW. Association of inherited steroidogenic genotype with body composition changes after androgen signaling inhibition (ASI) in men with biochemical recurrent (BCR), hormone-sensitive prostate cancer (HSPC). Journal of Clinical Oncology 42:108, 2024. e-Pub 2024.
2. Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer 27(7):R255-R265, 2020. e-Pub 2020. PMID: 32369771.
3. Karanika S, Karantanos T, Li L, Corn PG, Thompson TC. DNA damage response and prostate cancer: defects, regulation and therapeutic implications. Oncogene 34(22):2815-22, 2015. e-Pub 2015. PMID: 25132269.
4. Gardner LB, Corn PG. Hypoxic regulation of mRNA expression. Cell Cycle 7(13):1916-24, 2008. e-Pub 2008. PMID: 18604161.
5. Corn PG. Role of the Ubiquitin-proteasome system in Renal Cell Carcinoma. BMC Biochem 8 Suppl(1:S4):S4, 2007. e-Pub 2007. PMID: 18047741.
6. Corn PG, El-Deiry WS. Derangement of growth and differentiation control in oncogenesis. Bioessays 24(1):83-90, 2002. e-Pub 2002. PMID: 11782953.

Abstracts

1. Corn PG, Zurita AJ, Subudhi SK, Tu SM, Aparicio A, Araujo JC, Kim J, Wang J, Efstathiou E, Pagliaro LC, Logothetis CJ. Cabozantinib plus Androgen Deprivation Therapy in Patients with Androgen-Dependent Metastatic Prostate Cancer. ASCO - American Society of Clinical Oncology, 2017. e-Pub 2017.
2. Basourakos SP, Li L, Aparacio AM, Corn PG, Kim J, Thompson TC. Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions. Bentham Science. e-Pub 2017.
3. Scher HI, Morris MJ, Stadler WM, Higano CS, Halabi S, Smith MR, Basch EM, Fizazi K, Ryan CJ, Antonarakis ES, Corn PG, Liu G, DeBono JS, Schwartz LH, Beer TM, Kelly WK, Hussain M, Sartor AO, Kantoff PW, Armstrong AJ. The Prostate Cancer Working Group 3 (PCWG3) consensus for trials in castration-resistant prostate cancer (CRPC). J Clin Oncol 33(suppl; abstr 5000), 2015. e-Pub 2015.
4. Aparicio A, Shen L, Ning Tapia EL, Lu JF, Chen HC, Zhang J, Wu G, Wang X, Troncoso P, Corn PG, Thompson TC, Broom BM, Baggerly KA, Logothetis C, Maity SN. Molecular characterization of clinically defined aggressive variant prostate cancer (AVPCa) in prospectively collected tissues and corresponding patient derived xenografts (PDX). J Clin Oncol 33(suppl; abstr 5055), 2015. e-Pub 2015.
5. Corn PG, Tu SH, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Heath EI, Logothetis C, Aparicio A. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 33(suppl; abstr 5010), 2015. e-Pub 2015.
6. Campbell MT, Shah AY, Nautiyal KD, Hashemi N, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Association of chronic co-morbidities with long term survival with metastatic renal cell carcinoma (mRCC). J Clin Oncol 33(suppl 7; abstr 472). e-Pub 2015.
7. Campbell MT, Shah AY, Hashemi N, Nautiyal KD, Corn PG, Pagliaro LC, Jonasch E, Tannir NM. Long-term survivorship in patients (pts) with metastatic renal cell cancer (mRCC): A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7; abstr 510), 2015. e-Pub 2015.
8. Shah AY, Campbell MT, Nautiyal KD, Hashemi N, Matin SF, Vapriciyan AA, Rhines L, Moon B, Lewis VO, Lin PP, Prabhu SS, Rao G, Corn PG, Pagliaro LC, Mehran RJ, Wood CG, Jonasch E, Tannir NM. Long-term survivorship in patients with metastatic renal cell cancer (mRCC) managed with metastasectomy: A retrospective study from the MD Anderson Cancer Center (MDACC). J Clin Oncol 33(suppl 7; abstr 504), 2015. e-Pub 2015.
9. Bilen MH, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clini Oncol 32(suppl; abstr e16046), 2014. e-Pub 2014.
10. Jardim DL, De Melo Galiato D, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Phia-Paul. c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. J Clin Oncol 32(suppl 4; abstr 407), 2014. e-Pub 2014.
11. Corn PG, Tu SM, Zurita AJ, Araujo JC, Pagliaro LC, Logothetis C, Aparicio A. A randomized phase I/II study to examine the contribution of carboplatin to cabazitaxel for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) with and without anaplastic features. J Clin Oncol 32(suppl 4; abstr 148), 2014. e-Pub 2014.
12. Kalra S, Atkinson BJ, Matrana MR, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Prognosis of patients with metastatic renal cell carcinoma and pancreatic metastases. J Clin Oncol 32(suppl 4; abstr 527), 2014. e-Pub 2014.
13. Kalra S, Verma J, Atkinson BJ, Matin SF, Wood CG, Karam JA, Tamboli P, Sircar K, Rao P, Corn PG, Tannir NM, Jonasch E. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted-therapy era. J Clin Oncol 32(suppl 4; abstr 528), 2014. e-Pub 2014.
14. Jonasch E, Corn PG, Pagliaro LC, Lara P, Wang X, Do KA, Garza R, Bird S, Drabick JJ, Marcott V, Quinn D, Doyle A, Tannir NM. Randomized phase II CTEP study of MK2206 versus everolimus in VEGF inhibitor refractory renal cell carcinoma patients. J Clin Oncol, 2013. e-Pub 2013.
15. Atkinson BJ, Kalra S, Wang X, Bathala T, Perpich J, Corn PG, Tannir NM, Jonasch E. Outcomes associated with sunitinib alternative schedule compared to traditional schedule: a single-center experience. J Clin Oncol, 2013. e-Pub 2013.
16. Scher HI, Smith MR, Sweeney C, Corn PG, Logothetis C, Vogelzang NJ, Smith DC, Hussain M, George DJ, De Bono JS, Higano CS, Small EJ, Goldin J, Brown MS, Aftab DT, Noursalehi M, Weitzman A, Basch EM. An exploratory analysis of bone scan lesion area (BSLA), circulating tumor cell (CTC) change, pain reduction, and overall survival (OS) in patients (pts) with castration-resistant prostate cancer (CRPC) treated with cabozantinib (cabo): Updated results of a phase II nonrandomized expansion (NRE) cohort. J Clin Oncol, 2013. e-Pub 2013.
17. Dayyani F, Nogueras-Gonzalez GM, Slack R, Millikan RE, Zurita AJ, Araujo JC, Gallick GE, Logothetis C, Corn PG. Serum insulin to predict time to castration-resistant progression and overall survival in metastatic androgen-dependent prostate cancer (mADPCa). J Clin Oncol, 2013. e-Pub 2013.
18. Cauley DH, Atkinson BJ, Chaan NS, Millikan RE, Xiao L, Corn PG, Jonasch E, Tannir NM. mTOR inhibitor-associated noninfectious pneumonitis in patients with metastatic renal cell cancer: A single-center experience. J Clin Oncol, 2013. e-Pub 2013.
19. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results. J Clin Oncol, 2013. e-Pub 2013.
20. Hussain M, Corn PG, Michaelson D, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, MacLean D, Lee S, Lin MH, Zhu Y, Shi H, Mortimer P, George DJ. Safety, efficacy, and health-related quality of life (HRQoL) of the investigational single agent orteronel (ortl) in nonmetastatic castration-resistant prostate cancer (nmCRPC). J Clin Oncol, 2013. e-Pub 2013.
21. Corn PG, Varkaris A, Tapia EM, Araujo JC, Aparicio A, Tu SM, Zurita AJ, Efstathiou E, Qiao W, Wen S, Gallick GE, Logothetis C. Modulation of soluble c-Met, bone turnover markers, angiogenic factors, and c-Met in men with mCRPC treated with cabozantinib. J Clin Oncol, 2013. e-Pub 2013.
22. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do KA, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastatic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol, 2013. e-Pub 2013.
23. George DJ, Corn PG, Michaelson MD, Hammers HJ, Alumkal JJ, Ryan CJ, Bruce JY, Moran S, Lee SY, Mortimer P, Hussain M. Safety and activity of the investigational agent orteronel (ortl) without prednisone in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) and rising prostate-specific antigen (PSA): Updated results of a phase II study. J Clin Oncol, 2012. e-Pub 2012.
24. Siefker-Radtke AO, Kamat AM, Corn PG, Matin SF, Grossman HB, Millikan RE, Dinney CPN. Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center. J Clin Oncol, 2012. e-Pub 2012.
25. Smith MR, Sweeney C, Rathkopf DE, Scher HI, Logothetis C, George DJ, Higano CS, Yu EY, Harzstark AL, Small EJ, Sartor AO, Gordon MS, Vogelzang NJ, Smith DC, Hussain M, De Bono JS, Haas NB, Scheffold C, Lee Y, Corn PG. Cabozantinib (XL184) in chemotherapy-pretreated metastatic castration resistant prostate cancer (mCRPC): Results from a phase II nonrandomized expansion cohort (NRE). J Clin Oncol, 2012. e-Pub 2012.
26. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol, 2012. e-Pub 2012.
27. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experieince. J Clin Oncol, 2012. e-Pub 2012.
28. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated penumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol, 2012. e-Pub 2012.
29. Aparicio A, Harzstark L, Lin E, Corn P, Araujo J, Tu S, Pagliaro L, Millikan R, Arap W, Kim J, Ryan C, Zurita A, Tannir N, Lin A, Small J, Mathew P, Jones D, Troncoso P, Thall P, Logothetis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol, 2011. e-Pub 2011.
30. Hussain M, Smith MR, Sweeney C, Corn PG, Elfiky A, Gordon MS, Haas NB, Harzstark AL, Kurzrock R, Lara P, Lin C, Sella A, Small EJ, Spira AI, Vaishampayan UN, Vogelzang NJ, Scheffold C, Ballinger MD, Schimmoller F, Smith DC. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. J Clin Oncol, 2011. e-Pub 2011.
31. Bilen MA, Liu D, Mathew P, Pagliaro LC, Logothetis C, Araujo JC, Aparicio A, Corn PG, Hajdenberg J, Dakhil SR, Tu S. A randomized phase II study of bone-targeted therapy in advanced androgen-dependent prostate cancer. J Clin Oncol, 2011. e-Pub 2011.
32. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol, 2011. e-Pub 2011.
33. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol, 2011. e-Pub 2011.
34. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol, 2011. e-Pub 2011.
35. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol, 2010. e-Pub 2010.
36. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol, 2010. e-Pub 2010.
37. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol, 2009. e-Pub 2009.
38. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with systemic therapy without cytoreductive nephrectomy. J Clin Oncol, 2009. e-Pub 2009.
39. Tsao CC, Corn PG. Nutlin-3a induces growth arrest in kidney cancer cell lines in a p53-dependent manner. AACR - 100th Annual Meeting, 2009. e-Pub 2009.
40. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro LC, Corn P, Aparicio AM, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa:Clinical results and biomarker analysis. ASCO Proceedings 5093, 2008. e-Pub 2008.
41. Jonasch E, Corn P, Ashe RG, Do K, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 5104, 2007. e-Pub 2007.
42. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation stuatus is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. Journal of Clinical Oncology 15522, 2007. e-Pub 2007.

Book Chapters

1. Bilen, Mehemet A, Logothetis, Christopher J, Corn, Paul G. The Management of Prostate Cancer. In: MD Anderson Manual of Medical Oncology. 3rd Edition. McGraw-Hill, 2015.
2. Corn, Paul G, Logothetis, Christopher. The Management of Prostate Cancer. In: The M D Anderson Manual of Medical Oncology. 2nd Edition. McGraw-Hill, 2010.

Books (edited and written)

1. Corn Paul G. The MD Anderson Manual of Medical Oncology. Ed(s) 5th Edition, 2025.